A combination of approved and novel therapeutics improved survival rates and reduced both tumor volume and growth for those suffering from glioblastoma brain cancer.
Treatment with LAU-0901, a synthetic molecule that blocks pro-inflammatory platelet-activating factor, in addition to aspirin-triggered NPD1, reduced the size of damage areas in the brain, initiated repair mechanisms, and improved behavioral recovery following ischemic stroke.
GABA accelerates the breakdown of endocannabinoids in the brain. Endocannabinoids are critical for emotional processing. The findings could lead to the development of new treatments for emotional behavioral disorders.
Researchers conduct the first study to use nonharmful stress, like intermittent systemic hypoxia, to protect against disease in the first generation offspring in mice.
DHA treatment reduced the size of the damaged brain area and initiated a repair mechanism in animal models of stroke. DHA affected the levels of MANF and TREM2, two proteins critical for communication between brain cells.
Researchers confirm ACE inhibitors and ARBS medications may increase the risk of patients with COVID-19 developing more severe symptoms.
Researchers identify a group of neurons that are activated by oxytocin in an area of the female brain, but which are not present in the same area of a male mouse brain. Altered expression of these neurons may result in postpartum depression.
A neuroimaging study on house sparrows reveals changes in the dopaminergic system could be a physiological mechanism underlying the negative behavioral effects of chronic stress. The findings shed light on stress and resilience in wildlife and humans.
Researchers report they have discovers a new class of mediators, named elovanoids. These bioactive chemical messengers are created from omega-3 very long chain polyunsaturated fatty acid and released in response to cell injury. The findings are reported in Scientific Reports.